Rituximab Superior to Mycophenolate Mofetil in Pemphigus Vulgaris Survey
Mycophenolate mofetil, frequently former as a first-line corticosteroid-sparing agent for moderate to severe cases of the autoimmune blistering skin situation pemphigus vulgaris, has been came across to be inaccurate to the biologic agent rituximab. Mycophenolate mofetil is widely favorite as…